1/27
Looks like no tags are added yet.
Non covalent intereractions between drugs and binding
Electrostatic
Hydrogen bonding
Dipole Dipole
Van der Waals
Electrostatic interactions
Occur between oppositely charged groups
Strength depends on the surrounding environment, interactions can be stronger when buried away from water
Non-directional
Hydrogen bonds
specialized dipole dipole interactions
strength depends on surrounding environment (eg. hydrophobic environment)
highly directional, strength depends on geometry between donor and acceptor
requires donor and acceptor
Donor provides hydrogen eg OH, NH
Acceptor provides lone pair of e- eg. O, N
Dipole-Dipole
occurs between partial negative and partial positive charges of polar molecules
arise from differences in e-ivity between bonded atom, directional
strength depends on distance, orientation and surroundings
can be stronger in hydrophobic/less polar enviro
common in functional groups with strong dipoles eg. carbonyl
Van der Waals (disperson)
weak interactions, arise from temporary fluctuations in electron distribution, that create instantaneous dipoles.
Occur when atoms or molecular surfaces are in close contact, are non directional
strength increases with the amount of surface contact
Many weak interactions together can make an important contribution to drug–target binding Particularly important when a drug fits closely within a binding pocket
Desolvation during drug binding
When a drug is dissolved in the body, water molecules surround it
during binding: water molecules surrounding the drug and occupying the binding site must be pushed out
The interactions between water and the drug help stabilize the drug, so removing the interactions requires energy (energetic cost of desolvation)
Drug binding depends on whether new interactions with the target compensate for the interactions lost with water.
If the drug loses favourable interactions with water but forms even stronger interactions with the protein → binding is favourable.
If the drug loses favourable interactions with water but forms weak interactions with the protein → binding may not be favourable
Measuring Drug activity:
drug activity is measured using biological assay
experiment used to measure effect of drug on biological system
Assays can provide:
Qualitative info (whether effect occurs)
Quantitative info (magnitude of effect, eg decrease inflammation by 20%
Can be performed in vitro (outside whole living organism) or in vivo (inside living organism)
Assay selected depends on question
Types of Assays
different assays measure drug activity at different levels
Biochemical
Cell based
Tissue based
Biochemical assay:
Use purified targets or isolated biological components.
Measure how a drug interacts with a specific molecule, such as an enzyme.
Example: Does the drug inhibit an enzyme's activity?
cell based assay
Use intact, living cells.
Measure how cells respond when exposed to a drug.
Example: Does the drug prevent cancer cells from multiplying?
Tissue based assay
Use tissues containing multiple cells organized together.
Measure drug responses in a more complex biological environment.
Example: Does a drug cause a piece of heart tissue to contract less strongly?
potency
describes amount or concentration of drug required to produce a specified effect
Lower concentration/dose required → greater potency
Not the same as maximum effect (efficacy)
SAR
structure-activity relationships
how does changing structure affect drugs biological activity
Start with an active compound (a molecule that already produces a desired biological effect).
Make a structural modification (change part of the molecule).
Measure its biological activity using an assay.
Compare its activity with the original compound and other modified compounds.
Determine whether the structural change improved or reduced activity
identify which structural features are important for biological activity
SPR
Structure-Property Relationships (SPR)
how changing molecular structure affects physiochemical (eg. solubility, stability) and pharmacokinetic properties (eg. absorption, metabolism, excretion)
SPR and SAR are optimized together!!!
a molecule could have excelled biological activity but be unsuitable for development because: it didn’t dissolve well in water, gets metabolized too quickly, etc.)
what is meant by the term “drug like? what challenges are associated with designing a drug like compound
sufficient bio activity (potent enough to produce desired effect)
Selectivity – Preferential activity at the intended target
Suitable physicochemical properties (solubility, permeability)
Suitable biological properties (metabolic stability, ability to reach target)
Practical to develop (feasible synthesis, usable dosage form)
challenge: balancing properties that often have opposing effecs.
Common drug property measurements
Aqueous solubility: ability to dissolve in water •
pKa: tendency of an ionizable group to gain or lose aproton •
LogP / LogD: measures of lipophilicity •
Molecular weight: molecular size •
Permeability: ability to cross a biological barrier •
Melting point: related to solid-state properties andsolubility •
Metabolic stability: susceptibility to metabolism•
Protein binding: extent of drug binding to proteins
Property optimization
A drug will encounter many biological barriers before it can reach its target
biological activity and drug properties must be optimized to influence its ability to cross those barriers and reach target
Not all molecules in a dose reach bio target, so drug properties influence how much passes each barrier
water environment
polar
forms hydrogen bonding and dipole dipole interactions
hydrophilic molecules interact favourably
lipid/hydrocarbon environment
Non polar
No significant partial positive or negative charges, so polar interactions are limited. Main attractive force is van der waals
lipophilic/hydrophobic molecules interact favourably
DRAW THEM
membrane phospholipid
equations for pKa
membrane permeability
Many molecules can cross lipid bilayers by passive diffusion
interior of lipid bilayer is non polar, so drug must enter lipid environment to cross membrane
drug must be sufficiently water soluble to dissolve in aqueous biological fluids, BUT also have sufficient membrane permeability
successful drugs have appropriate balance
Ionization and solubility
many drugs contain acidic or basic functional groups that can exist in ionized (charged) or neutral forms
ionizable groups can gain or lose proton
Ionized forms more water-soluble
neutral forms cross membranes more readily by passive diffusion
proportion of each form depends on pH and pKa
Approximately 75% of drugs are basic, 20% acidic, and 5% neutral/non-ionizable.
pKa vs pH
pH describes acidity of surrounding solution (low pH = high H+ concentration)
pKa describes how easily an ionizable group gives up a proton (low pKa, group readily loses H aka strong acid), a characteristic
comparing pH and pKa helps predict whether a group is predominantly protonated or deprotonated
Acids vs Bases, Protonation
Acids: proton donor
pH < pKa (environment has relatively more H, so acid keeps its proton) NEUTRAL
when pH > pKa (environment has relatively less H+, so acid loses its proton), NEGATIVELY CHARGED
base: proton acceptor
pH < pKa (CA) environment has more H+, protonated base keeps its proton. POSITIVELY CHARGED
pH > pKa (CA) environment has less H+, so protonated base loses its proton. NEUTRAL
neutral when pH < pKa, charged when pH > pKa
Bases: neutral when pH> pKa (of cb), charged when pH < pKa
Amphiprotic
certain functional groups can act as acid or base depending on chemical environment
Aqueous pH
Drug ionization occurs in an aqueous environment, which limits pH range relevant to drug development conditions
H3O+: pKa ~ 1.7 (BASE)
H2OL pKA ~ 15.7 (ACID)
Imagine a drug with an ionizable group with a pKa of 30. the pH conditions normally encountered in the body wont cause it to change its ionization state.
if pKa is far outside aqueous range, ionization is not relevant.
why do molecules with permanent charges problematic for drug delivery
do not cross membranes easily
are eliminated quiclky by kidneys
Why are weak acids or bases generally more suitable as drugs than strong acids or bases?
The pKa values of weak acids and bases are typically close to physiological pH (around 7), so at pH 7 there is always a small fraction of the drug in its neutral form, which can cross biological membranes more easily. In contrast, strong acids and bases are almost fully ionized at all physiological pH values, leaving very little of the neutral form available. As a result, their ability to cross membranes is greatly reduced and absorption becomes slow or inefficient